AI-guided pathology analysis can help predict immunotherapy response in rare cancers
Researchers at MD Anderson Cancer Center have utilized AI-based pathology analysis to predict how patients with rare cancers respond to immunotherapy. The study demonstrates that AI can efficiently analyze tumor microenvironments to guide personalized treatment decisions.
Why it matters
This advancement could significantly improve the efficacy of cancer treatments by allowing clinicians to tailor immunotherapy to individual patient profiles more quickly than manual analysis.
by University of Texas MD Anderson Cancer Center
The report is a straightforward summary of a scientific study published in a peer-reviewed journal.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in